KUMAR, S Pranush, Tarang JADAV, Amit Kumar SAHU, Moumita Ghosh CHOWDHARY, Ankit SIWACH, Harit PATEL, Sagarkumar PATEL, Niraj RAJPUT, Amit SHARD, Amit Suresh KHAIRNAR and Pinaki SENGUPTA. Assessment of metabolic stability and pharmacokinetics by LC-MS/MS and establishment of the safe dose of IMID-2, a novel anticancer molecule under drug discovery. BIOMEDICAL CHROMATOGRAPHY. HOBOKEN: WILEY, 2023, vol. 37, No 6, p. 1-8. ISSN 0269-3879. Available from: https://dx.doi.org/10.1002/bmc.5618.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Assessment of metabolic stability and pharmacokinetics by LC-MS/MS and establishment of the safe dose of IMID-2, a novel anticancer molecule under drug discovery
Authors KUMAR, S Pranush, Tarang JADAV, Amit Kumar SAHU, Moumita Ghosh CHOWDHARY, Ankit SIWACH, Harit PATEL, Sagarkumar PATEL, Niraj RAJPUT, Amit SHARD, Amit Suresh KHAIRNAR (356 India, belonging to the institution) and Pinaki SENGUPTA (guarantor).
Edition BIOMEDICAL CHROMATOGRAPHY, HOBOKEN, WILEY, 2023, 0269-3879.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.800 in 2022
RIV identification code RIV/00216224:14110/23:00130692
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/bmc.5618
UT WoS 000955749900001
Keywords in English acute oral toxicity; IMID-2; LC-MS; MS; metabolic stability; pharmacokinetics
Tags 14110515, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 2/2/2024 11:45.
Abstract
Pyruvate kinase (PK) M2 activators ramp up glycolysis in cancer cells, leading to a reversal of the Warburg effect in cancer cells. A promising PKM2 activator molecule, IMID-2, developed by the National Institute of Pharmaceutical Education and Research-Ahmedabad showed promising anticancer activity against MCF-7 and COLO-205 cell lines, which represent breast and colon cancer. Its physicochemical properties, like solubility, ionization constant, partition coefficient and distribution constant, have already been established. Its metabolic pathway is also well established through in vitro and in vivo metabolite profiling and reported previously. In this study, we have evaluated the metabolic stability of IMID-2 using LC-MS/MS and investigated the safety aspect of the molecule through an acute oral toxicity study. In vivo studies in rats confirmed that the molecule is safe even at a dose level of 175 mg/kg. Furthermore, a pharmacokinetic study of IMID-2 was also carried out using LC-MS/MS to understand its absorption, distribution, metabolism, and excretion profile. The molecule was found to have promising bioavailability through the oral route. This research work is thus another step in the drug testing of this promising anticancer molecule. The molecule can be considered to be a potential anticancer lead based on the earlier report substantiated by current findings.
PrintDisplayed: 10/7/2024 20:38